Nearly 80% of patients with metastatic uveal melanoma experienced skin toxicities with tebentafusp, a targeted immunotherapy, according to a study that also suggests that the presence of skin reactions is associated with improved survival.
Health Professionals
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
The phase 3 IOB-013/KN-D18 trial (NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab (Keytruda) for the first-line treatment of patients with advanced melanoma will continue without modifications following a recommendation from an independent data monitoring committee (IDMC).
Mayo Clinic study finds dysfunctional white blood cells linked to heightened melanoma risk
ROCHESTER, Minn. — About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition — called monoclonal B-cell lymphocytosis (MBL) — do not experience any symptoms, a new study shows they may have an elevated risk for several health complications, including melanoma, a form of skin cancer. The findings, by Mayo Clinic researchers, are published in a new paper in the Journal of Clinical Oncology.
Study From Researchers at Fox Chase Cancer Center and Johns Hopkins Kimmel Cancer Center Shows Aged Male Fibroblasts Increase Melanoma Treatment Resistance
PHILADELPHIA (September 6, 2024) — In a study published today in the prestigious journal Cell, researchers from Fox Chase Cancer Center and Johns Hopkins Kimmel Cancer Center showed changes that occur with age in male skin fibroblasts contributed to an increase in the spread of melanoma cells and made cancer cells resistant to targeted therapy.